Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

Gene Emery  |  May 9, 2017

NEW YORK (Reuters Health)—Pfizer’s expensive arthritis drug tofacitinib has been shown to produce a remission in nearly 1 in 5 patients with moderate to severe ulcerative colitis, but long-term remission persists in fewer than half of those cases. In a series of studies published in the May 4 New England Journal of Medicine, researchers reported…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Tofacitinibulcerative colitis

Institute for Clinical Economic Review Final Report on RA Treatments

Mary Beth Nierengarten  |  May 4, 2017

On April 7, 2017, the Institute for Clinical and Economic Review (ICER) published its final report, titled, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.1 The stated objective of the report was to assess the comparative clinical effectiveness of the targeted immune modulators (TIMs) used to treat patients with moderate to severe active rheumatoid…

Filed under:Drug UpdatesPractice SupportProfessional TopicsRheumatoid Arthritis Tagged with:Institute for Clinical and Economic Review (ICER)targeted immune modulators (TIMs)Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value

Valeant Prices Psoriasis Treatment at $3,500 Per Month

Reuters Staff  |  April 21, 2017

(Reuters)—Canadian drug maker Valeant Pharmaceuticals International Inc. said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. Brodalumab (Siliq) is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant says. Drugmakers are facing intense criticism from…

Filed under:Drug Updates Tagged with:brodalumabcostsdrug costsPsoriasisValeant Pharmaceuticals

Drug Reduction Strategies, Disease Control for Patients with RA in Remission

Mary Beth Nierengarten  |  April 20, 2017

WASHINGTON, D.C.—Clinical aspects of managing patients with rheumatoid arthritis (RA) in remission were discussed by a panel of experts at the 2016 ACR/ARHP Annual Meeting during the session titled Rheumatoid Arthritis—Clinical Aspects IV: Managing Patients in Remission. Among the issues raised were strategies to taper or discontinue biologic therapies, as well as clinical predictors of…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)drugoutcomepatient careRAreductionRemissionRheumatoid arthritisrheumatologytherapyTNFitumor necrosis factor inhibitor

Rheumatology Coding Corner Question: Billing Infusion Procedure with JW Modifier

From the College  |  April 20, 2017

An 82-year-old female established patient diagnosed with ankylosing spondylitis in multiple joints returns to the office for her second infliximab infusion. She denies any fevers, cough or concurrent illness. Her joint pain is 7 on a scale of 1–10. She complains of achy pain in the cervical, lumbar and sacral regions of her spine. She…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodinginfliximabInfusionoffice visitpatient carePractice Managementrheumatologistrheumatology

Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier

From the College  |  April 20, 2017

Take the challenge. CPT: 99214-25, 96413, 96375, 96361-59, J1745 x 4 J1745 JW* x 36, J1200 x1 ICD-10: M45.09, T50.995A, R06.02, E66.3, Z68.2 Rationale Modifier 25 is appropriate to use because it indicates the patient received a significant, separately identifiable E/M service on the same day as the infliximab infusion. This E/M service entailed the…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodinginfliximabInfusionoffice visitpatient carePractice Managementrheumatologistrheumatology

Biosimilar Drugs Raise Questions around Treatment Efficacy, Quality, Safety

Thomas R. Collins  |  April 20, 2017

WASHINGTON, D.C.—Challenges abound for the manufacturing of biosimilar drugs—from their sheer size compared with small molecule drugs to the unknowable proprietary aspects of the originator drugs—an expert said at the 2016 ACR/ARHP Annual Meeting in a session titled Immunology Update: Biologic Agents: From Nature to Protein Engineering to Biosimilars. Above all, because biosimilars are copies…

Filed under:Biologics/DMARDsDrug UpdatesMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)BiosimilarsDrugsefficacypatient careQualityResearchrheumatologistrheumatologySafetytherapy

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Sneha Patel, MD, Monica Mohile, MD, & Arundathi Jayatilleke, MD  |  April 19, 2017

A 56-year-old African American man presents to the emergency department with polyarthralgias and a fever of 103ºF. One month prior to admission, he presented with right knee pain and swelling. Blood cultures grew S. epidermidis. He was treated for presumed septic arthritis complicated by MSSE bacteremia. He was treated with meropenem and a prolonged course…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:anchoring biasArthritiscase reportClinicalDiagnosisdiagnostic testingGoutinflammationjointoutcomepatient carepolyarthralgiaRArheumatologistrheumatologyseropositive rheumatoid arthritisTreatment

Ustekinumab Has Longer Efficacy Duration than TNFIs for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 28, 2017

When compared with TNFIs, ustekinumab demonstrated a longer drug survival rate in patients with severe plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:biologic drugsdrug survivalplaque psoriasisustekinumab

Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors

Thomas R. Collins  |  March 20, 2017

WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link. The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)CancerinhibitorJuvenile idiopathic arthritisPediatricsrateResearchrheumatologyriskTNFTreatment

  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences